Business
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
NEEDHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral
About this update from Candel Therapeutics, Inc.
[{"type":"text","content":"NEEDHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced new clinical data will be presented in the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, MA and the 27th Annual Meeting of the Society for Neuro-Oncology (SNO) in Tampa Bay, FL. Details are as follows: 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Poster Presentation Title: Dynamic analyses of tumor microenvironment modulation by CAN-2409 treatment using Kaede photoconvertible transgenic mice Presenter: Anne R. Diers, PhD, Director of Early Research, Candel Therapeutics Abstract Number: 1134Date/Time: Friday, November 11, 2022, from 9 am – 8:30 pm ETLocation: Hall C, Omni Boston Hotel, Boston, MA or Virtual Oral Presentation Title: First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma Presenter: Patrick Y. Wen, MD, Director, Cancer for Neuro-Oncology, Dana-Farber Cancer Institute; Professor, Neurology, Harvard Medical School; Principal Investigator for Candel TherapeuticsAbstract Session: Late Breaking 204Date/Time: Friday, November 11, 2022, from 11:25 am – 11:55 am ETLocation: Hall B2, Omni Boston Hotel, Boston, MA or Virtual 27th Annual Meeting of the Society for Neuro-Oncology (SNO) Oral Presentation Title: Enriched TCR/BCR VDJ rearrangements correlate with MRI and survival outcomes in patients with recurrent high-grade glioma treated with CAN-3110 Presenter: Alexander Ling, PhD, Postdoctoral Research Fellow, Brigham and Women’s Hospital Abstract Session: Clinical Trial IDate/Time: Friday, November 18, 2022, from 5:30 pm – 5:35 pm ETLocation: Ballroom B, Tampa Convention Center, Tampa, FL Details from the presentations will be available following the events on the Candel website at https://www.candeltx.com/media/. About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on helping patients fight cancer with viral immunotherapies that elicit a systemic anti-tumor immune response. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-medi...